BWA
JAZZ icon

Basecamp Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Basecamp Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.71K Hold
32
– – ﹤0.01% 1068
2026
Q1 		$6.05K Buy
+32
New +$5.59K ﹤0.01% 1139

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Basecamp Wealth Advisors's JAZZ Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 32 shares worth $7.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Basecamp Wealth Advisors first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Basecamp Wealth Advisors held 32 shares of Jazz Pharmaceuticals worth $7.71K as of Q2 2026.
  • Basecamp Wealth Advisors left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1068 holding.
  • Basecamp Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.